Full-Time

Senior Product Manager

Updated on 5/21/2025

Click Therapeutics

Click Therapeutics

51-200 employees

Develops software as prescription medical treatments

Compensation Overview

$140k - $175k/yr

+ Annual Bonus + Equity Package

Senior

New York, NY, USA

Hybrid working model with at least 3 days in office each week.

Category
Technical Product Management
Product Management
Product
Required Skills
Agile
Product Management
SCRUM
Requirements
  • 5+ years of experience working as a Product Owner or Product Manager in an Agile and/or SCRUM environment for mobile products.
  • Experience in bringing a software product to market, or managing a major release for a live product.
  • Experience working on cross-functional teams to deliver software applications.
  • Excellent verbal and written communication skills, demonstrated through the creation of strong presentation materials, product requirements documents & user stories.
  • Strong facilitation skills, with experience in managing the requests & expectations of multiple stakeholders and upper management.
  • Strong technical leadership, project management, analytical problem solving, business analysis, and troubleshooting skills.
  • Experience with systems design and/or foundational coding concepts.
  • Experience translating technical concepts and solutions to non-technical and executive audiences.
  • Experience conducting user research through both qualitative and quantitative methods.
  • Passionate about improving healthcare, have experience in the space or a personal connection.
Responsibilities
  • Work in collaboration with scientific, business, and engineering leaders to rapidly define and develop features that deliver therapeutic value to our patients & our partners.
  • Understand scientific concepts and identify opportunities to translate ideas into testable, scalable products and prototypes.
  • Deeply understand and synthesize the complexities of the healthcare environment including regulations, existing clinical workflows, and patient journeys into high potential product opportunities.
  • Facilitate workshops with external business partners to gather requirements, drive consensus, and clarify strategic direction.
  • Translate requirements into clear user stories that can be efficiently communicated to the development team to deliver into working software.
  • Work closely with the development team, acting as a key driver for Agile ceremonies such as Stand up, Retrospective, Sprint Planning & Sprint Reviews.
  • Manage timelines and a product roadmap to organize timely feature releases and minimize release delays.
  • Drive effective teamwork, communication, collaboration and commitment across multiple departments.
  • Interface with scientific and commercial collaboration partners throughout the product design, development, and launch of the product.
Desired Qualifications
  • Individuals who are fluent in speaking, writing and reading in Japanese are strongly preferred.
  • Background or previous experience in neuroscience, psychiatry, psychology, behavior change, digital health or a related field.
  • Experience in consulting or client services.
  • Experience in Cultural Change/Digital Transformation projects.
  • Experience conducting clinical research.
  • Experience working with technologies including, but not limited to, ReactNative, Node.js, AWS.

Click Therapeutics develops software applications that function as prescription medical treatments for patients with various health conditions. These digital therapeutics are designed to change cognitive and neurobehavioral mechanisms related to diseases, and they are tested through rigorous randomized controlled trials to ensure safety and effectiveness. After validation, the company seeks FDA clearance to market these applications as class II medical devices. Unlike traditional pharmaceuticals, Click Therapeutics' products are prescribed by physicians and reimbursed by payers, allowing for a unique revenue model. Their collaboration with Boehringer Ingelheim to create a digital therapeutic for schizophrenia highlights their commitment to advancing digital health solutions. The goal of Click Therapeutics is to provide effective, evidence-based software treatments that can improve patient outcomes and address unmet medical needs.

Company Size

51-200

Company Stage

Debt Financing

Total Funding

$161.6M

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA authorization for CT-132 boosts their credibility in digital therapeutics.
  • Acquisition of Better Therapeutics expands their portfolio into obesity and cardiometabolic diseases.
  • Collaborations with Otsuka and Boehringer Ingelheim strengthen their market position.

What critics are saying

  • Integration challenges with Better Therapeutics' assets may delay product development.
  • Regulatory hurdles could impact approval timelines for new digital therapeutics.
  • Dependence on partnerships could affect market reach if collaborations change.

What makes Click Therapeutics unique

  • Click Therapeutics specializes in software as medical treatments for unmet medical needs.
  • Their Clickometrics® platform personalizes user experience to optimize engagement and outcomes.
  • Partnerships with pharma giants like Boehringer Ingelheim enhance their market credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Company Match

Unlimited Paid Time Off

Flexible Work Arrangement

Stock Options

Performance Bonus

Fertility Treatment Support

Professional Development Budget

Commuter Benefits

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

6%

2 year growth

7%
Hit Consultant
Apr 15th, 2025
Click Therapeutics Obtains Fda Authorization For First Prescription Digital Therapeutic For Migraine Prevention

What You Should Know: – Click Therapeutics, Inc. (“Click”), a leader in the rapidly evolving field of prescription medical treatments, encompassing both prescription digital therapeutics (PDTs) and software-enhanced drug™ therapies has received FDA marketing authorization for CT-132, the first prescription digital therapeutic specifically indicated for the preventive treatment of episodic migraine in adults aged 18 and older.– The FDA granted a De Novo Classification Request for CT-132, signifying the novel nature of this digital intervention. This PDT is intended for adjunctive use alongside existing acute and/or other preventive migraine treatments, offering patients an additional tool in their management strategy.CT-132 Prescription Digital TherapeuticThe CT-132 prescription digital therapeutic is indicated for the preventive treatment of episodic migraine in patients 18 years of age and older. It is intended for adjunctive use alongside acute and / or other preventive treatments for migraine. The FDA’s decision was primarily based on compelling data from the pivotal ReMMi-D (Reduction in Monthly Migraine Days, NCT05853900) study. This study evaluated CT-132 in patients already taking standard-of-care prescription migraine medications (including acute, first-line preventive, and second-line preventive treatments) and successfully met its primary endpoint of significantly reducing monthly migraine days.ReMMi-D and ReMMiD-C StudiesFurther supporting the authorization were results from the ReMMiD-C bridging study (NCT06004388)

Business Wire
Mar 20th, 2025
Dassault Systèmes Intensifies the MEDIDATA Commitment to Patient Experience With Investment in Click Therapeutics for Digital Therapeutics Beyond Clinical Trials

Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today announced its investment in Click Therapeutics, a leader in prescription digital therapeutics ...

The Healthcare Technology Report
Nov 28th, 2024
Click Therapeutics Launches Software-Enhanced Drug Therapies

Click Therapeutics launches Software-Enhanced Drug therapies.

Business Wire
Oct 8th, 2024
Click Therapeutics Founder and CEO David Benshoof Klein Named to 2024 PharmaVoice 100 List

NEW YORK-(BUSINESS WIRE)-David Benshoof Klein, founder and chief executive officer of Click Therapeutics, has been honored as a PharmaVoice 100 winner.

Business Wire
Aug 13th, 2024
Otsuka Precision Health and Click Therapeutics Announce Launch of Rejoyn(TM), the First-And-Only Prescription Digital Therapeutic Cleared by the FDA for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms

PRINCETON, N.J. & NEW YORK-(BUSINESS WIRE)-Otsuka Precision Health, Inc. (OPH) and Click Therapeutics, Inc., (Click) announce today the commercial launch of Rejoyn(TM).